{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:05:23Z","timestamp":1792134323942,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"crossref","award":["NIHR303144"],"award-info":[{"award-number":["NIHR303144"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate whether a two-step, \u2018stage-gated\u2019 reporting approach could improve the positive predictive value (PPV) of biparametric (bp)MRI for prostate cancer (PCa) screening compared to conventional Likert\/PI-RADS scoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This retrospective secondary analysis utilised data from IP1-PROSTAGRAM\u2014a prospective, population-based study of men aged 50\u201369 years who underwent PCa screening with bpMRI, ultrasound and prostate-specific antigen (PSA) testing between October 2018 and May 2019 at two centres (NCT03702439). MRI scans from IP1-PROSTAGRAM were retrospectively evaluated using the \u2018stage-gated\u2019 approach: three radiologists independently reviewed limited MRI sequences (axial T2-weighted and b1500 diffusion-weighted images) and classified scans as positive or negative; if positive, the remaining bpMRI images were reviewed and a hypothetical \u201cdecision-to-biopsy\u201d made.<\/jats:p>\n                    <jats:p>The PPV of \u2018stage-gated\u2019 reading was compared to PI-RADS and Likert scores\u2009\u2265\u20094 from the original IP1-PROSTAGRAM bpMRI reports. The reference standard was IP1-PROSTAGRAM biopsy results with grade group (GG)\u2009\u2265\u20092 cancer considered significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 408 participants (median age 57 years [IQR 53, 61]), 405 had MRI scans available for secondary analysis. The prevalence of GG\u2009\u2265\u20092 cancer was 4% (17\/405). The \u2018stage-gated\u2019 reporting approach achieved a PPV of 53% (95% CI: 30, 75; 8\/15), compared to 29% (95% CI: 15, 47; 8\/28) and 30% (95% CI: 17, 46; 11\/37) for Likert and PI-RADS\u2009\u2265\u20094 pathways, respectively. The \u2018stage-gated\u2019 approach halved the number of recommended biopsies while maintaining similar cancer detection rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The \u2018stage-gated\u2019 reporting approach, using limited sequences for the initial read, may improve the PPV and benefit-to-harm ratio of MRI-based screening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Question<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>The PPV of MRI in PCa screening is low, likely because conventional assessment systems are not optimised for low disease prevalence populations<\/jats:italic>\n                      .\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Findings<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>A two-step, \u2018stage-gated\u2019 reading approach achieved a PPV of 53% (8\/15), compared to 29% (8\/28) for Likert and 30% (11\/37) for PI-RADS scores\u2009\u2265\u20094<\/jats:italic>\n                      .\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Clinical relevance<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>The \u2018stage-gated\u2019 reporting approach, which uses limited sequences for the initial read, may improve the PPV and benefit-to-harm ratio of MRI-based screening by reducing unnecessary biopsies. Prospective evaluation is needed to confirm these findings in real-world screening settings<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00330-025-12250-4","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T12:57:48Z","timestamp":1771505868000},"page":"5678-5687","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Diagnostic accuracy of a \u2018stage-gated\u2019 approach for reporting prostate screening MRI: \u201cIs less more?\u201d"],"prefix":"10.1007","volume":"36","author":[{"given":"Natasha","family":"Thorley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Parry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Brembilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Giganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Eldred-Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Mayor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair","family":"Lamb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny L.","family":"Hubbard Cristinacce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry H.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heminder K.","family":"Sokhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar R.","family":"Padhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hashim U.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9865-0260","authenticated-orcid":false,"given":"Shonit","family":"Punwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"12250_CR1","unstructured":"Publications Office of the European Union (2022) Cancer screening in the European Union. https:\/\/data.europa.eu\/doi\/10.2777\/867180. Accessed 1 Oct 2025"},{"key":"12250_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","volume":"76","author":"J Hugosson","year":"2019","unstructured":"Hugosson J, Roobol MJ, M\u00e5nsson M et al (2019) A 16-yr follow-up of the European randomized study of screening for prostate cancer. Eur Urol 76:43\u201351. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.009","journal-title":"Eur Urol"},{"key":"12250_CR3","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1056\/nejmoa031918","volume":"350","author":"IM Thompson","year":"2004","unstructured":"Thompson IM, Pauler DK, Goodman PJ et al (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level \u22644.0 ng per milliliter. N Engl J Med 350:2239\u20132246. https:\/\/doi.org\/10.1056\/nejmoa031918","journal-title":"N Engl J Med"},{"key":"12250_CR4","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1001\/jama.2018.0154","volume":"319","author":"RM Martin","year":"2018","unstructured":"Martin RM, Donovan JL, Turner EL et al (2018) Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial. JAMA 319:883\u2013895. https:\/\/doi.org\/10.1001\/jama.2018.0154","journal-title":"JAMA"},{"key":"12250_CR5","doi-asserted-by":"publisher","unstructured":"Schoots IG, Haider MA, Punwani S, Padhani AR (2025) MRI in prostate cancer screening: a review and recommendations, from the AJR special series on screening. AJR Am J Roentgenol. https:\/\/doi.org\/10.2214\/AJR.24.32588","DOI":"10.2214\/AJR.24.32588"},{"key":"12250_CR6","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1001\/jamaoncol.2024.0734","volume":"10","author":"T Fazekas","year":"2024","unstructured":"Fazekas T, Shim SR, Basile G et al (2024) Magnetic resonance imaging in prostate cancer screening: a systematic review and meta-analysis. JAMA Oncol 10:745\u2013754. https:\/\/doi.org\/10.1001\/jamaoncol.2024.0734","journal-title":"JAMA Oncol"},{"key":"12250_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.eururo.2025.05.038","volume":"88","author":"IG Schoots","year":"2025","unstructured":"Schoots IG, Ahmed HU, Albers P et al (2025) Magnetic resonance imaging-based biopsy strategies in prostate cancer screening: a systematic review. Eur Urol 88:247\u2013260. https:\/\/doi.org\/10.1016\/j.eururo.2025.05.038","journal-title":"Eur Urol"},{"key":"12250_CR8","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.eururo.2019.05.029","volume":"76","author":"M van der Leest","year":"2019","unstructured":"van der Leest M, Isra\u00ebl B, Cornel EB et al (2019) High diagnostic performance of short magnetic resonance imaging protocols for prostate cancer detection in biopsy-na\u00efve men: the next step in magnetic resonance imaging accessibility. Eur Urol 76:574\u2013581. https:\/\/doi.org\/10.1016\/j.eururo.2019.05.029","journal-title":"Eur Urol"},{"key":"12250_CR9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/bju.14759","volume":"124","author":"M Alabousi","year":"2019","unstructured":"Alabousi M, Salameh JP, Gusenbauer K et al (2019) Biparametric vs multiparametric prostate magnetic resonance imaging for the detection of prostate cancer in treatment-na\u00efve patients: a diagnostic test accuracy systematic review and meta-analysis. BJU Int 124:209\u2013220. https:\/\/doi.org\/10.1111\/bju.14759","journal-title":"BJU Int"},{"key":"12250_CR10","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.eururo.2024.09.035","volume":"87","author":"JJ Twilt","year":"2025","unstructured":"Twilt JJ, Saha A, Bosma JS et al (2025) Evaluating biparametric versus multiparametric magnetic resonance imaging for diagnosing clinically significant prostate cancer: an international, paired, noninferiority, confirmatory observer study. Eur Urol 87:240\u2013250. https:\/\/doi.org\/10.1016\/j.eururo.2024.09.035","journal-title":"Eur Urol"},{"key":"12250_CR11","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1001\/jama.2025.13722","volume":"334","author":"ABCD Ng","year":"2025","unstructured":"Ng ABCD, Asif A, Agarwal R et al (2025) Biparametric vs multiparametric MRI for prostate cancer diagnosis: the PRIME diagnostic clinical trial. JAMA 334:1170\u20131179. https:\/\/doi.org\/10.1001\/jama.2025.13722","journal-title":"JAMA"},{"key":"12250_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.euo.2023.03.009","volume":"6","author":"D Eldred-Evans","year":"2023","unstructured":"Eldred-Evans D, Tam H, Sokhi H et al (2023) An evaluation of screening pathways using a combination of magnetic resonance imaging and prostate-specific antigen: results from the IP1-PROSTAGRAM study. Eur Urol Oncol 6:295\u2013302. https:\/\/doi.org\/10.1016\/j.euo.2023.03.009","journal-title":"Eur Urol Oncol"},{"key":"12250_CR13","doi-asserted-by":"publisher","first-page":"e059482","DOI":"10.1136\/bmjopen-2021-059482","volume":"12","author":"R Nam","year":"2022","unstructured":"Nam R, Patel C, Milot L et al (2022) Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial. BMJ Open 12:e059482. https:\/\/doi.org\/10.1136\/bmjopen-2021-059482","journal-title":"BMJ Open"},{"key":"12250_CR14","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.euf.2024.02.006","volume":"10","author":"C Wetterauer","year":"2024","unstructured":"Wetterauer C, Matthias M, Pueschel H et al (2024) Opportunistic prostate cancer screening with biparametric magnetic resonance imaging (VISIONING). Eur Urol Focus 10:332\u2013338. https:\/\/doi.org\/10.1016\/j.euf.2024.02.006","journal-title":"Eur Urol Focus"},{"key":"12250_CR15","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s00330-023-10019-1","volume":"34","author":"E Messina","year":"2024","unstructured":"Messina E, La Torre G, Pecoraro M et al (2024) Design of a magnetic resonance imaging-based screening program for early diagnosis of prostate cancer: preliminary results of a randomized controlled trial\u2014prostate cancer secondary screening in Sapienza (PROSA). Eur Radiol 34:204\u2013213. https:\/\/doi.org\/10.1007\/s00330-023-10019-1","journal-title":"Eur Radiol"},{"key":"12250_CR16","doi-asserted-by":"publisher","first-page":"e048144","DOI":"10.1136\/bmjopen-2020-048144","volume":"11","author":"T Marsden","year":"2021","unstructured":"Marsden T, Lomas DJ, McCartan N et al (2021) ReIMAGINE prostate cancer screening study: protocol for a single-centre feasibility study inviting men for prostate cancer screening using MRI. BMJ Open 11:e048144. https:\/\/doi.org\/10.1136\/bmjopen-2020-048144","journal-title":"BMJ Open"},{"key":"12250_CR17","doi-asserted-by":"publisher","first-page":"e000057","DOI":"10.1136\/bmjonc-2023-000057","volume":"2","author":"CM Moore","year":"2023","unstructured":"Moore CM, Frangou E, McCartan N et al (2023) Prevalence of MRI lesions in men responding to a GP-led invitation for a prostate health check: a prospective cohort study. BMJ Oncol 2:e000057. https:\/\/doi.org\/10.1136\/bmjonc-2023-000057","journal-title":"BMJ Oncol"},{"key":"12250_CR18","doi-asserted-by":"publisher","unstructured":"Thorley N, Parry T, Giganti F et al (2025) Diagnostic accuracy of abbreviated biparametric MRI for prostate cancer screening: a prospective feasibility study (ReIMAGINE Study). Eur Radiol. https:\/\/doi.org\/10.1007\/s00330-025-11837-1","DOI":"10.1007\/s00330-025-11837-1"},{"key":"12250_CR19","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamaoncol.2020.7456","volume":"7","author":"D Eldred-Evans","year":"2021","unstructured":"Eldred-Evans D, Burak P, Connor MJ et al (2021) Population-based prostate cancer screening with magnetic resonance imaging or ultrasonography: the IP1-PROSTAGRAM study. JAMA Oncol 7:395\u2013402. https:\/\/doi.org\/10.1001\/jamaoncol.2020.7456","journal-title":"JAMA Oncol"},{"key":"12250_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.eururo.2015.08.052","volume":"69","author":"JC Weinreb","year":"2016","unstructured":"Weinreb JC, Barentsz JO, Choyke PL et al (2016) PI-RADS prostate imaging\u2014reporting and data system: 2015, version 2. Eur Urol 69:16\u201340. https:\/\/doi.org\/10.1016\/j.eururo.2015.08.052","journal-title":"Eur Urol"},{"key":"12250_CR21","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.7150\/jca.27344","volume":"9","author":"SW Xie","year":"2018","unstructured":"Xie SW, Wang YQ, Dong BJ et al (2018) A nomogram based on a TRUS five-grade scoring system for the prediction of prostate cancer and high grade prostate cancer at initial TrUs-guided biopsy. J Cancer 9:4382\u20134390. https:\/\/doi.org\/10.7150\/jca.27344","journal-title":"J Cancer"},{"key":"12250_CR22","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","volume":"76","author":"B Turkbey","year":"2019","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA et al (2019) Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol 76:340\u2013351. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.033","journal-title":"Eur Urol"},{"key":"12250_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/01621459.1927.10502953","volume":"22","author":"EB Wilson","year":"1927","unstructured":"Wilson EB (1927) Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 22:209\u2013212. https:\/\/doi.org\/10.1080\/01621459.1927.10502953","journal-title":"J Am Stat Assoc"},{"key":"12250_CR24","doi-asserted-by":"publisher","unstructured":"Day E, Eldred-Evans D, Prevost AT et al (2022) Adjusting for verification bias in diagnostic accuracy measures when comparing multiple screening tests\u2014an application to the IP1-PROSTAGRAM study. BMC Med Res Methodol. https:\/\/doi.org\/10.1186\/s12874-021-01481-w","DOI":"10.1186\/s12874-021-01481-w"},{"key":"12250_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/0284185117702181","volume":"59","author":"KC Godley","year":"2018","unstructured":"Godley KC, Syer TJ, Toms AP et al (2018) Accuracy of high b-value diffusion-weighted MRI for prostate cancer detection: a meta-analysis. Acta Radiol 59:105\u2013113. https:\/\/doi.org\/10.1177\/0284185117702181","journal-title":"Acta Radiol"},{"key":"12250_CR26","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMoa2406050","volume":"391","author":"J Hugosson","year":"2024","unstructured":"Hugosson J, Godtman RA, Wallstrom J et al (2024) Results after four years of screening for prostate cancer with PSA and MRI. N Engl J Med 391:1083\u20131095. https:\/\/doi.org\/10.1056\/NEJMoa2406050","journal-title":"N Engl J Med"},{"key":"12250_CR27","doi-asserted-by":"publisher","first-page":"e2354577","DOI":"10.1001\/jamanetworkopen.2023.54577","volume":"7","author":"T Nordstr\u00f6m","year":"2024","unstructured":"Nordstr\u00f6m T, Annerstedt M, Glaessgen A et al (2024) Repeated prostate cancer screening using prostate-specific antigen testing and magnetic resonance imaging a secondary analysis of the STHLM3-MRI randomized clinical trial. JAMA Netw Open 7:e2354577. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.54577","journal-title":"JAMA Netw Open"},{"key":"12250_CR28","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.euo.2020.06.007","volume":"3","author":"F Giganti","year":"2020","unstructured":"Giganti F, Allen C, Emberton M et al (2020) Prostate imaging quality (PI-QUAL): a new quality control scoring system for multiparametric magnetic resonance imaging of the prostate from the PRECISION trial. Eur Urol Oncol 3:615\u2013619. https:\/\/doi.org\/10.1016\/j.euo.2020.06.007","journal-title":"Eur Urol Oncol"},{"key":"12250_CR29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.euros.2022.11.013","volume":"47","author":"O Windisch","year":"2023","unstructured":"Windisch O, Benamran D, Dariane C et al (2023) Role of the prostate imaging quality PI-QUAL score for prostate magnetic resonance image quality in pathological upstaging after radical prostatectomy: a multicentre European study. Eur Urol Open Sci 47:94\u2013101. https:\/\/doi.org\/10.1016\/j.euros.2022.11.013","journal-title":"Eur Urol Open Sci"},{"key":"12250_CR30","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.ejca.2008.02.016","volume":"44","author":"P Taylor","year":"2008","unstructured":"Taylor P, Potts HWW (2008) Computer aids and human second reading as interventions in screening mammography: two systematic reviews to compare effects on cancer detection and recall rate. Eur J Cancer 44:798\u2013807. https:\/\/doi.org\/10.1016\/j.ejca.2008.02.016","journal-title":"Eur J Cancer"},{"key":"12250_CR31","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/S1470-2045(23)00298-X","volume":"24","author":"K L\u00e5ng","year":"2023","unstructured":"L\u00e5ng K, Josefsson V, Larsson AM et al (2023) Artificial intelligence-supported screen reading versus standard double reading in the mammography screening with artificial intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study. Lancet Oncol 24:936\u2013944. https:\/\/doi.org\/10.1016\/S1470-2045(23)00298-X","journal-title":"Lancet Oncol"},{"key":"12250_CR32","unstructured":"NIHR National Institute for Health and Care Research (2025) World-leading AI trial to tackle breast cancer launched. https:\/\/www.nihr.ac.uk\/news\/world-leading-ai-trial-tackle-breast-cancer-launched. Accessed 7 Mar 2025"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-12250-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-025-12250-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-12250-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T10:17:33Z","timestamp":1781864253000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-025-12250-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["12250"],"URL":"https:\/\/doi.org\/10.1007\/s00330-025-12250-4","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Prof. Shonit Punwani.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare relationships with the following companies: F.G. reports consulting fees from SpectraCure and Procept outside of the submitted work. He has received speaker fees from Bayer and Siemens, is a member of the Scientific Editorial Board of European Radiology (section: Urogential), and the Guest Editor of the Active Surveillance of Prostate Cancer: MRI and beyond Collection; as such, he has not participated in the selection or review processes for this article. S.P. reports consulting fees from NVISION IMAGING, Gold Standard Phantoms and Quibim outside of the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"One of the authors (T.P.) has significant statistical expertise.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was obtained from all subjects (patients) in the original IP1-PROSTAGRAM study. The original study consent form included a specific optional clause allowing the use of data for future retrospective research. The current study only includes participants who provided this consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained for the original IP1-PROSTAGRAM study. Ethical approval was granted by the UK National Research Ethics Committee (reference: 8\/LO\/1338).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Participants from IP1-PROSTAGRAM have been included in prior publications: Eldred-Evans et al [\n                      \n                      ], Eldred-Evans et al [\n                      \n                      ], and Day et al [\n                      \n                      ].","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}